Vertex presents new ALYFTREK data on cystic fibrosis

Vertex said interim data from an open-label extension study in children ages 2 to 5 showed recovery of exocrine pancreatic function in some participants treated with ALYFTREK. The company also presented additional abstracts on CFTR modulators at the North American Cystic Fibrosis Conference.